Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 
Brian  Engelhardt

Brian Engelhardt, M.D.

Assistant Professor of Medicine (Hematology and Oncology)
Hematologist/Oncologist

Profile

Dr. Engelhardt is a medical oncologist who specializes in hematological malignancies and stem cell transplantation.

His clinical interests include: acute myeloid leukemia, stem cell transplantation, umbilical cord blood transplantation, Graft-versus-Host disease (GVHD), and metabolic complications following transplant.
Read more...

Dr. Engelhardt is a medical oncologist who specializes in hematological malignancies and stem cell transplantation.

His clinical interests include: acute myeloid leukemia, stem cell transplantation, umbilical cord blood transplantation, Graft-versus-Host disease (GVHD), and metabolic complications following transplant.  More than 100,000 patients undergo stem cell transplantation annually throughout the world, with the primary indication being hematological malignancy. Patients undergoing stem cell transplantation are at risk for numerous acute and long-term complications including: graft-versus-host disease (GVHD), infectious complications, and new-onset metabolic disorders.  Many of these disease states are related to abnormalities in immune regulation and lymphocyte migration. Dr. Engelhardt has an ongoing program of unique and innovative research investigating tissue-homing characteristics of immune effector and suppressor cells to determine their role in complications of allogeneic stem cell transplantation.  His research has specifically focused on 1) the use of umbilical cord blood as an alternative donor source to minimize GVHD, 2) tissue-homing T cell subsets as predictors / biomarkers of GVHD outcomes, and 3) the physiology and immunology of glucose metabolism after transplant.  It is notable that this last line of research represents an entirely new field of study in stem cell transplantation which integrates transplant immunology with endocrinology.

Education
  • Undergraduate School & Degree: University of Michigan, B.S., 1996
  • Medical School & Degree: Case Western Reserve University, MD, 2000 
  • Internship / Residency, Department of Medicine, University of North Carolina, Chapel Hill, NC, 2003 
  • Clinical Fellow, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, 2003-2006 
  • Vanderbilt University, Nashville, Tennessee, Master of Science in Clinical Investigation; 2008
  • Board & Certifications: Internal Medicine, Hematology and Oncology 
Publications
  • Das-Gupta E, Greinix H, Jacobs R, Zhou L, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Jagasia M. Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure. Haematologica [print-electronic]. 2014 Nov; 99(11): 1746-52. PMID: 25150260, PMCID: PMC4222474, PII: haematol.2014.108217, DOI: 10.3324/haematol.2014.108217, ISSN: 1592-8721.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25150260.
  • Sengsayadeth S, Savani BN, Jagasia M, Goodman S, Greer JP, Chen H, Chinratanalab W, Kassim AA, Engelhardt BG. Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials. Bone Marrow Transplant [print-electronic]. 2014 Feb; 49(2): 236-40. PMID: 24096824, PMCID: PMC3946331, PII: bmt2013157, DOI: 10.1038/bmt.2013.157, ISSN: 1476-5365.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24096824.
  • Ragon BK, Clifton C, Chen H, Savani BN, Engelhardt BG, Kassim AA, Vaughan LA, Lucid C, Jagasia M. Geographic distance is not associated with inferior outcome when using long-term transplant clinic strategy. Biol. Blood Marrow Transplant [print-electronic]. 2014 Jan; 20(1): 53-7. PMID: 24120525, PII: S1083-8791(13)00450-3, DOI: 10.1016/j.bbmt.2013.10.004, ISSN: 1523-6536.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24120525.
  • Reddy NM, Oluwole O, Greer JP, Engelhardt BG, Jagasia MH, Savani BN. Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma. Exp. Hematol [print-electronic]. 2014 Jan; 42(1): 39-45. PMID: 24096123, PII: S0301-472X(13)00747-9, DOI: 10.1016/j.exphem.2013.09.012, ISSN: 1873-2399.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24096123.
  • Vaughan LA, Vu M, Sengsayadeth S, Lucid C, Clifton C, McCarty K, Hagaman D, Domm J, Kassim A, Chinratanalab W, Goodman S, Greer J, Frangoul H, Engelhardt BG, Jagasia M, Savani BN. New allergies after cord blood transplantation. Cytotherapy. 2013 Oct; 15(10): 1259-65. PMID: 23993300, PII: S1465-3249(13)00550-1, DOI: 10.1016/j.jcyt.2013.05.018, ISSN: 1477-2566.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23993300.
  • Jagasia M, Greinix H, Robin M, Das-Gupta E, Jacobs R, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Socie G. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol. Blood Marrow Transplant [print-electronic]. 2013 Jul; 19(7): 1129-33. PMID: 23623892, PII: S1083-8791(13)00186-9, DOI: 10.1016/j.bbmt.2013.04.018, ISSN: 1523-6536.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23623892.
  • Weitkamp JH, Koyama T, Rock MT, Correa H, Goettel JA, Matta P, Oswald-Richter K, Rosen MJ, Engelhardt BG, Moore DJ, Polk DB. Necrotising enterocolitis is characterised by disrupted immune regulation and diminished mucosal regulatory (FOXP3)/effector (CD4, CD8) T cell ratios. Gut [print-electronic]. 2013 Jan; 62(1): 73-82. PMID: 22267598, PMCID: PMC3606820, PII: gutjnl-2011-301551, DOI: 10.1136/gutjnl-2011-301551, ISSN: 1468-3288.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22267598.
  • Engelhardt BG, Sengsayadeth SM, Jagasia M, Savani BN, Kassim AA, Lu P, Shyr Y, Yoder SM, Rock MT, Crowe JE. Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival. Exp. Hematol [print-electronic]. 2012 Dec; 40(12): 974-982.e1. PMID: 22885125, PMCID: PMC3611587, PII: S0301-472X(12)00343-8, DOI: 10.1016/j.exphem.2012.08.002, ISSN: 1873-2399.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22885125.
  • Sengsayadeth SM, Jagasia M, Engelhardt BG, Kassim A, Strickland SA, Goodman S, Lucid C, Vnencak-Jones CL, Greer JP, Savani BN. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant [print-electronic]. 2012 Dec; 47(12): 1535-7. PMID: 22659680, PII: bmt201288, DOI: 10.1038/bmt.2012.88, ISSN: 1476-5365.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22659680.
  • Jacobs R, Tran U, Chen H, Kassim A, Engelhardt BG, Greer JP, Goodman SG, Clifton C, Lucid C, Vaughan LA, Savani BN, Jagasia M. Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. Bone Marrow Transplant [print-electronic]. 2012 Nov; 47(11): 1470-3. PMID: 22484321, PII: bmt201256, DOI: 10.1038/bmt.2012.56, ISSN: 1476-5365.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22484321.
  • Jagasia M, Clark WB, Brown-Gentry KD, Crawford DC, Fan KH, Chen H, Kassim A, Greer JP, Engelhardt BG, Savani BN. Genetic variation in donor CTLA-4 regulatory region is a strong predictor of outcome after allogeneic hematopoietic cell transplantation for hematologic malignancies. Biol. Blood Marrow Transplant [print-electronic]. 2012 Jul; 18(7): 1069-75. PMID: 22178694, PII: S1083-8791(11)01080-9, DOI: 10.1016/j.bbmt.2011.12.518, ISSN: 1523-6536.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22178694.
  • Engelhardt BG, Jagasia SM, Crowe JE, Griffith ML, Savani BN, Kassim AA, Lu P, Weitkamp JH, Moore DJ, Yoder SM, Rock MT, Jagasia M. Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity. Blood [print-electronic]. 2012 Mar 3/8/2012; 119(10): 2417-21. PMID: 22262764, PMCID: PMC3311262, PII: blood-2011-10-384750, DOI: 10.1182/blood-2011-10-384750, ISSN: 1528-0020.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22262764.
  • Clark WB, Brown-Gentry KD, Crawford DC, Fan KH, Snavely J, Chen H, Savani BN, Kassim A, Greer JP, Schuening FG, Engelhardt BG, Jagasia MH. Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD. Blood [print-electronic]. 2011 Jul 7/28/2011; 118(4): 1140-4. PMID: 21628416, PII: blood-2010-09-310011, DOI: 10.1182/blood-2010-09-310011, ISSN: 1528-0020.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21628416.
  • Engelhardt BG, Jagasia M, Savani BN, Bratcher NL, Greer JP, Jiang A, Kassim AA, Lu P, Schuening F, Yoder SM, Rock MT, Crowe JE. Regulatory T cell expression of CLA or a(4)ß(7) and skin or gut acute GVHD outcomes. Bone Marrow Transplant [print-electronic]. 2011 Mar; 46(3): 436-42. PMID: 20577222, PMCID: PMC3217583, PII: bmt2010127, DOI: 10.1038/bmt.2010.127, ISSN: 1476-5365.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20577222.
  • Lucid CE, Savani BN, Engelhardt BG, Shah P, Clifton C, Greenhut SL, Vaughan LA, Kassim A, Schuening F, Jagasia M. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant [print-electronic]. 2011 Mar; 46(3): 426-9. PMID: 20581885, PII: bmt2010152, DOI: 10.1038/bmt.2010.152, ISSN: 1476-5365.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20581885.
  • Griffith ML, Jagasia MH, Misfeldt AA, Chen H, Engelhardt BG, Kassim A, Savani BN, Survant M, Jagasia SM. Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant [print-electronic]. 2011 Jan; 17(1): 86-92. PMID: 20561594, PII: S1083-8791(10)00254-5, DOI: 10.1016/j.bbmt.2010.06.010, ISSN: 1523-6536.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20561594.
  • Tedeschi SK, Jagasia M, Engelhardt BG, Domm J, Kassim AA, Chinratanalab W, Greenhut SL, Goodman S, Greer JP, Schuening F, Frangoul H, Savani BN. Early lymphocyte reconstitution is associated with improved transplant outcome after cord blood transplantation. Cytotherapy [print-electronic]. 2011 Jan; 13(1): 78-82. PMID: 20586668, DOI: 10.3109/14653249.2010.495114, ISSN: 1477-2566.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20586668.
  • Engelhardt BG, Crowe JE. Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells. Curr. Top. Microbiol. Immunol. 2010; 341: 121-46. PMID: 20563712, PMCID: PMC3793903, DOI: 10.1007/82_2010_24, ISSN: 0070-217X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20563712.
  • Engelhardt BG, Holland DW, Brandt SJ, Chinratanalab W, Goodman SA, Greer JP, Jagasia MH, Kassim AA, Morgan DS, Ruffner KL, Schuening FG, Wolff S, Bitting R, Sulur P, Stein RS. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes. Leuk. Lymphoma. 2007 Sep; 48(9): 1728-35. PMID: 17786708, PII: 781802102, DOI: 10.1080/10428190701534374, ISSN: 1042-8194.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17786708.